Royalty Pharma (RPRX) news
Recent news
Royalty Pharma: Including rights to 1% royalty future net sales
Royalty Pharma, a leading entity in the biopharmaceutical royalty sector, has continued to expand its portfolio through strategic transactions that include rights to a percentage of future net sales from various therapeutic products. One such example is the company’s recent agreement with Denali…
AInvest Wire · Aug 12, 2026Royalty Pharma & Zealand Pharma in $100M funding deal
Royalty Pharma and Zealand Pharma have entered into a $100 million funding agreement, marking a significant development in the biopharmaceutical sector. Under the terms of the deal, Royalty Pharma will provide Zealand Pharma with a substantial capital infusion in exchange for a royalty stream tied…
AInvest Wire · Aug 12, 2026Royalty Pharma raises FY portfolio receipts outlook
AInvest Wire · Aug 5, 2026Royalty Pharma: outlook 2026 portfolio receipts $3,400 mln to $3,500 mln, interest paid $350 mln to $360 mln
AInvest Wire · Aug 5, 2026Royalty Pharma acquires royalty interest in AstraZeneca’s Cliramitug for up to $425 million from Neurimmune
AInvest Wire · Jul 22, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.